Showing papers in "Thrombosis Research in 2020"

TL;DR: The findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophYLaxis towards high-prophylactic doses, even in the absence of randomized evidence.

TL;DR: There is an urgent need to improve specific VTE diagnostic strategies and investigate the efficacy and safety of thromboprophylaxis in ambulatory COVID-19 patients.

TL;DR: The very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia is confirmed in this updated analysis.

TL;DR: Of concern, is the observation that anticoagulation may be inadequate in many circumstances, highlighting the need for alternative or additional therapies.

TL;DR: The observation of highly pathological data on anti-phospholipid-antibodies, von Willebrand Factor (VWF) and Factor VIII points towards massive endothelial stimulation and damage with release of VWF from Weibel-Palade bodies.

TL;DR: A number of pressing issues were identified by this review, including defining the true incidence of VTE in COVID patients, developing algorithms to identify those susceptible to develop thrombotic complications and severe disease, determining the role of biomarkers and/or scoring systems to stratify patients' risk, and designing adequate and feasible diagnostic protocols for PE.

TL;DR: The incidence of asymptomatic DVT is similar to that described in other series, and higher cut-off levels for D-dimer might be necessary for the diagnosis of DVT in COVID-19 patients.

TL;DR: Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID–19 patients requiring mechanical ventilation.

TL;DR: The common COVID-19 abnormal hematological indexes on admission included hyperfibrinogenemia, lymphopenia, the elevation of D-dimer, and leuk Openia, which were significantly different between the mild/moderate and severe CO VID-19 groups.

TL;DR: To raise awareness for possible benefits of examining known COVID-19 patients presenting sudden clinical worsening with CT pulmonary angiography instead of standard non-contrast chest CT, a poster is presented at the American Academy of Thoracic Surgeons annual meeting.

TL;DR: VTE represents a frequent complication in hospitalized COVID-19 patients and often occurs as PE and may complicate the course of Coronavirus Disease 2019.

TL;DR: It is suggested that COVID-19 associated PE represents in situ immunothrombosis rather than venous thromboembolism, although the origin of thrombotic lesions in CO VID-19 patients remains largely unknown.

TL;DR: Patients with severe COVID-19 have a higher level of D-dimer than those with non-severe disease, and D- dimer greater than 0.5 μg/ml is associated with severe infection in patients with CO VID-19.

TL;DR: This review summarizes the hematological changes in patients infected with SARS-CoV-2 and possible underlying mechanisms of thrombocytopenia development and a dynamic decrease in platelet counts may be useful in the prognosis of patients with COVID-19.

TL;DR: Six irreversible lower limb ischemia and two thoracic aortic free floating thrombi are described and further studies are needed to evaluate the necessity of therapeutic anticoagulation in COVID-19 patients.

TL;DR: It is demonstrated how the complement system is able to activate the coagulation cascade and platelets, inhibit fibrinolysis and stimulate endothelial cells, and how these interactions see clinical relevance in several disorders where overactive complement results in a prothrombotic clinical presentation and how it could be clinically relevant in COVID-19.

TL;DR: COVID-19 pneumonia could be associated with an increased risk of venous thrombosis and antiphospholipid antibodies might be involved in thromBosis in patients, according to a small but systematic literature review.

TL;DR: Venous thrombosis is common in patients with severe COVID-19 pneumonia and many of these thromBoses may be immunothromboses due to local inflammation, rather than thromboembolic disease.

TL;DR: The decision to escalate the dose of anticoagulation was based on laboratory values characterizing the severity of COVID-19 such as rising D-dimer levels, and the use of TA was significantly associated with increased risk of bleeding.

TL;DR: Observational data suggest an acquired prothrombotic state may contribute to the pathophysiology of COVID-19, and D-dimer levels and trends are associated with outcomes, but they have limited performance characteristics as prognostic tests.

TL;DR: To determine the incidence of PE in hospitalised patients with COVID-19 and the diagnostic yield of Computer Tomography Pulmonary Angiography (CTPA) for PE, a retrospective review of single-centre data of all CTPA studies in patients with suspected or confirmed CO VID-19 identified from Electronic Patient Records is reviewed.

TL;DR: The knowledge gaps that exist in multiple aspects of CRT are described and the need for large collaborative studies to improve the care of patients with CRT is described.

TL;DR: The most recent evidence on management of high-estrogen states in women at high-risk of thrombosis is reviewed, as well as emerging data on unique populations such as transgender women.

TL;DR: This review surveys papers addressing issues related to severe COVID-19, characterized by enhanced lung microvascular loss, hypercytokinemia, hypoxemia and thrombosis, and points out how the delicate and physiological homeostatic function of the endothelium, which turns into a disastrous battlefield of the complex interaction between “cyTokine and coagulative storms”, can be irreparably compromised and result in systemic inflammatory complications.

TL;DR: LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients and was not associated with thrombotic complications.